4/29
07:00 am
azn
AstraZeneca results: Q1 2026
Low
Report
AstraZeneca results: Q1 2026
4/28
07:00 am
azn
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
Low
Report
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
4/27
07:00 am
azn
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
Low
Report
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
4/27
02:27 am
azn
AstraZeneca PLC (AZN) Announces Positive Results From a Prespecified Interim Analysis of the I CAN Phase III Trial [Yahoo! Finance]
Low
Report
AstraZeneca PLC (AZN) Announces Positive Results From a Prespecified Interim Analysis of the I CAN Phase III Trial [Yahoo! Finance]
4/26
04:34 pm
azn
AstraZeneca PLC (AZN): One of the Best Low Risk High Growth Firms [Yahoo! Finance]
Low
Report
AstraZeneca PLC (AZN): One of the Best Low Risk High Growth Firms [Yahoo! Finance]
4/20
11:26 am
azn
AstraZeneca Achieves Positive Phase III Results for COPD Drug [TheStreet.com]
Low
Report
AstraZeneca Achieves Positive Phase III Results for COPD Drug [TheStreet.com]
4/20
07:00 am
azn
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Low
Report
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
4/10
01:01 pm
azn
Astrazeneca (AZN) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Astrazeneca (AZN) had its "overweight" rating reaffirmed by Morgan Stanley.
4/2
09:57 am
azn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]
Low
Report
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]
4/2
07:00 am
azn
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
Low
Report
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
4/2
02:05 am
azn
Deutsche Bank Maintains Sell on AstraZeneca (AZN) [Yahoo! Finance]
Low
Report
Deutsche Bank Maintains Sell on AstraZeneca (AZN) [Yahoo! Finance]
3/27
07:00 am
azn
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Low
Report
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
3/20
01:31 am
azn
Low
Report
3/18
02:07 pm
azn
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.
3/15
05:59 pm
azn
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
Low
Report
AstraZeneca PLC (AZN) Secures US Priority Review For Candidate Breast Cancer Treatment [Yahoo! Finance]
3/12
06:11 pm
azn
Astrazeneca (AZN) is now covered by
Weiss Ratings. They set a "buy (b)" rating on the stock.
Low
Report
Astrazeneca (AZN) is now covered by
Weiss Ratings. They set a "buy (b)" rating on the stock.
3/12
09:24 am
azn
Low
Report
3/10
08:30 am
azn
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
Low
Report
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
3/9
07:00 am
azn
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Medium
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
2/20
07:00 am
azn
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
Low
Report
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
2/13
07:00 am
azn
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
Neutral
Report
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
2/11
09:00 am
azn
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
Low
Report
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
2/10
07:00 am
azn
AstraZeneca results: FY and Q4 2025
Low
Report
AstraZeneca results: FY and Q4 2025
2/6
03:11 pm
azn
AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
2/4
01:40 pm
azn
Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]
Low
Report
Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]